67
Participants
Start Date
January 31, 2010
Primary Completion Date
November 30, 2011
Study Completion Date
December 31, 2011
CTS-1027
CTS-1027 supplied in 5 and 10 mg tablets, 15 mg taken twice daily, for up to 48 weeks
Pegylated interferon
Pegylated interferon, 180 micrograms in 0.5 ml of solution injected subcutaneously (SQ) once per week, for up to 48 weeks. Packaged in single use syringes.
Ribavirin
Ribavirin, 200 mg capsules taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg for up to 48 weeks.
Liver Institute of Virginia, Newport News
Digestive Healthcare of Georgia, Atlanta
Consultants of Clinical Research, Ohio GI and Liver Institute, Cincinnati
Henry Ford Medical Center-Columbus, Novi
MN Clinical Research Center, Plymouth
St. Louis University, St Louis
Tulane University Health Sciences Center, New Orleans
Advanced Liver Therapies - Baylor College of Medicine, Houston
VA Medical Center, Houston, Houston
South Denver Gastroenterology, Englewood
University of Colorado Health Science Center, Denver
University of Utah Health Science Center, Salt Lake City
Scripps Clinic, La Jolla
VA Medical Center, San Diego, San Diego
Fundacion de Investigacion de Diego, Santurce
Lead Sponsor
Conatus Pharmaceuticals Inc.
INDUSTRY